Omnicell Inc. (NASDAQ:OMCL) saw strong trading volume on Friday . 160,274 shares traded hands during mid-day trading, a decline of 7% from the previous session’s volume of 172,802 shares.The stock last traded at $35.95 and had previously closed at $35.96.

A number of research analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Omnicell from a “hold” rating to a “sell” rating in a research note on Wednesday, May 4th. FBR & Co reaffirmed a “buy” rating and issued a $35.00 price target on shares of Omnicell in a research note on Monday, May 2nd. Finally, Topeka Capital Markets cut their price objective on shares of Omnicell from $38.00 to $37.00 and set a “buy” rating for the company in a report on Monday, March 21st. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $37.25.

The stock has a 50 day moving average price of $34.03 and a 200 day moving average price of $29.88. The stock has a market capitalization of $1.29 billion and a price-to-earnings ratio of 53.95.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, April 28th. The company reported $0.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.26 by $0.09. The firm had revenue of $171 million for the quarter, compared to analyst estimates of $167.18 million. The company’s revenue was up 47.1% compared to the same quarter last year. During the same quarter last year, the firm earned $0.29 earnings per share. Analysts forecast that Omnicell Inc. will post $1.56 earnings per share for the current fiscal year.

In other news, Director Sara J. White sold 2,000 shares of the business’s stock in a transaction dated Thursday, May 5th. The shares were sold at an average price of $31.76, for a total transaction of $63,520.00. Following the transaction, the director now directly owns 40,433 shares in the company, valued at $1,284,152.08. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Jorge R. Taborga sold 23,827 shares of the business’s stock in a transaction dated Tuesday, April 26th. The stock was sold at an average price of $30.00, for a total transaction of $714,810.00. Following the transaction, the vice president now owns 52,667 shares in the company, valued at $1,580,010. The disclosure for this sale can be found here.

Other hedge funds recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP increased its stake in Omnicell by 3.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,641,466 shares of the company’s stock worth $51,017,000 after buying an additional 51,729 shares in the last quarter. Paradigm Capital Management Inc. NY increased its stake in Omnicell by 32.4% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 412,600 shares of the company’s stock worth $12,824,000 after buying an additional 100,900 shares in the last quarter. Century Capital Management LLC increased its stake in Omnicell by 1.5% in the fourth quarter. Century Capital Management LLC now owns 353,669 shares of the company’s stock worth $10,992,000 after buying an additional 5,234 shares in the last quarter. Principal Financial Group Inc. increased its stake in Omnicell by 3.0% in the fourth quarter. Principal Financial Group Inc. now owns 241,880 shares of the company’s stock worth $7,518,000 after buying an additional 6,979 shares in the last quarter. Finally, Edge Asset Management Inc. increased its stake in Omnicell by 41.0% in the fourth quarter. Edge Asset Management Inc. now owns 378,276 shares of the company’s stock worth $11,757,000 after buying an additional 110,035 shares in the last quarter.

Omnicell, Inc (Omnicell) is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety. The Company operates through two operating segments: Automation and Analytics, and Medication Adherence.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.